AI Image
FDA recalls GLP-1 drug, other injectable medication over sterility concerns
LiveNOW from FOX • • business
Key Points:
- Apothecary Pharma is voluntarily recalling 23 vials of injectable drugs nationwide due to concerns over sterility, including 22 vials of compounded tirzepatide and one vial of NAD+ injection.
- The FDA classified the recall as Class II, indicating that serious health problems are unlikely, and no illnesses or injuries have been reported in connection with these products.
- The recall follows a December 2025 FDA warning letter to Apothecary Pharma for deficiencies in sterile drug manufacturing, though the agency has not linked those issues to the current recall.
- Consumers should stop using the affected products, check their pharmacy records, and contact their healthcare provider; those experiencing symptoms like fever or swelling after injection should seek medical care.
- The recall began on September 24 and is ongoing, with specific lot numbers and expiration dates provided for the tirzepatide and NAD+ injections.
